Advertisement
Canada markets close in 4 hours

  • S&P/TSX

    21,945.58
    +60.20 (+0.28%)
     

  • S&P 500

    5,098.59
    +50.17 (+0.99%)
     

  • DOW

    38,228.66
    +142.86 (+0.38%)
     

  • CAD/USD

    0.7310
    -0.0013 (-0.18%)
     

  • CRUDE OIL

    83.89
    +0.32 (+0.38%)
     

  • Bitcoin CAD

    86,834.17
    -727.32 (-0.83%)
     

  • CMC Crypto 200

    1,322.42
    -74.11 (-5.31%)
     

  • GOLD FUTURES

    2,349.10
    +6.60 (+0.28%)
     

  • RUSSELL 2000

    1,995.35
    +14.23 (+0.72%)
     

  • 10-Yr Bond

    4.6630
    -0.0430 (-0.91%)
     

  • NASDAQ

    15,918.93
    +307.17 (+1.97%)
     

  • VOLATILITY

    15.30
    -0.07 (-0.46%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6837
    +0.0016 (+0.23%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

Stocks in play: Appili Therapeutics Inc.

Baystreet.ca

Announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance of new patent claims for ATI-1501, Appili’s liquid oral reformulation of the antibiotic metronidazole. A notice of allowance is issued by the USPTO to indicate that the application has passed the examination. Appili Therapeutics Inc. shares T.APLI are trading up $0.01 at $0.06.

Read: